首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (2): 179-185.doi: 10.3969/j.issn.1006-7795.2019.02.005

• 肿瘤的免疫治疗与代谢 • 上一篇    下一篇

双肾上腺素样激酶1不同剪接体通过激活JNK通路增强胰腺癌细胞的增生能力

张媛媛, 葛洋, 安广宇   

  1. 首都医科大学附属北京朝阳医院肿瘤科, 北京 100020
  • 收稿日期:2019-01-17 出版日期:2019-03-21 发布日期:2019-04-15
  • 通讯作者: 安广宇 E-mail:agybjcy@163.com
  • 基金资助:
    国家自然科学基金(81802738)。

DCLK1 alternative variants enhance proliferation of pancreatic cancer cells by activating JNK pathway

Zhang Yuanyuan, Ge Yang, An Guangyu   

  1. Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
  • Received:2019-01-17 Online:2019-03-21 Published:2019-04-15
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81802738).

摘要: 目的 研究双肾上腺素样激酶1(doublecortin-like kinase 1,DCLK1)长、短亚型对人胰腺癌增生能力的影响,并探讨其分子机制。方法 分别将空载(PCMV6-AC-GFP)、DCLK1亚型1和DCLK1亚型4真核表达质粒转染胰腺癌PANC-1细胞,G418筛选法构建DCLK1不同亚型稳定过表达的细胞系;通过定量实时聚合酶链式反应(quantitative real time polymerase chain reaction,qRT-PCR)和Western blotting法鉴定DCLK1长、短亚型的表达情况;实时无标记细胞分析仪(real-time cell analysis,RTCA)技术检测DCLK1长、短亚型表达对PANC-1细胞增生能力的影响;Western blotting法检测DCLK1对丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)通路的影响;利用c-Jun氨基末端激酶(c-Jun N-terminal kinase,JNK)通路特异性抑制剂SP600125处理DCLK1稳转细胞,检测JNK通路抑制对胰腺癌细胞增生能力的影响。结果 DCLK1长、短亚型的过表达显著促进胰腺癌细胞的增生能力(P<0.05),并且促进MAPK通路中JNK的磷酸化水平以及JNK通路靶分子CMYC、CD44和CyclinD1的表达(P<0.05),而对MAPK通路中细胞外调节蛋白激酶(extracellular regulated protein kinases,ERK)和p38的磷酸化无明显影响(P>0.05);SP600125抑制JNK的磷酸化,可以显著降低DCLK1对JNK通路的激活以及对胰腺癌细胞的促增生能力(P<0.05)。结论 DCLK1长、短亚型均可以通过激活JNK通路促进胰腺癌细胞的增生能力。

关键词: 胰腺癌, 双肾上腺素样激酶1长、短亚型, 增生, JNK通路

Abstract: Objective To investigate the effects of long-and short-isoform of doublecortin-like kinase 1 (DCLK1) on the proliferation of human pancreatic cancer and further to explore the molecular mechanism. Methods The control (PCMV6-AC-GFP), DCLK1 isoform 1 and DCLK1 isoform 4 eukaryotic expression plasmids were transfected into pancreatic cancer PANC-1 cells. G418 screening method was used to construct stable cell lines overexpressing long-and short-isoform of DCLK1. Expression of long-and short-isoform of DCLK1 were determined by quantitative real time polymerase chain reaction(qRT-PCR) and Western blotting. The effect of long-and short-isoform of DCLK1 on the proliferation of PANC-1 cells were detected with real-time cell analysis (RTCA) technology. The effect of DCLK1 on mitogen-activated protein kinase (MAPK) pathway was detected with Western blotting. DCLK1 stabilizing cells were treated with specific c-Jun N-terminal kinase (JNK) pathway inhibitor SP600125 to detect the effect of JNK pathway inhibition on the proliferation of pancreatic cancer cells. Results Overexpression of long-and short-isoform of DCLK1 remarkably promoted the proliferation of pancreatic cancer cells (P<0.05), increased the phosphorylation of JNK in MAPK pathway and the expression of target molecules CMYC, CD44 and CyclinD1 in JNK pathway (P<0.05). No significant influence on the phosphorylation of ERK and p38 were detected (P>0.05). SP600125 inhibited the phosphorylation of JNK and markedly decreased the activation of JNK pathway and the proliferation of pancreatic cancer cells by DCLK1 (P<0.05). Conclusion Both long-and short-isoform of DCLK1 promote the proliferation of pancreatic cancer cells via activating JNK pathway.

Key words: pancreatic cancer, doublecortin-like kinase 1 long and short isoforms, proliferation, JNK pathway

中图分类号: